Expert Review of Vaccines最新文献_第4页

Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance. 预防新生儿败血症的疫苗：重点关注B群链球菌、肺炎克雷伯菌和大肠杆菌，以应对日益严重的抗菌素耐药性。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/14760584.2026.2622690

Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo

{"title":"Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance.","authors":"Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo","doi":"10.1080/14760584.2026.2622690","DOIUrl":"10.1080/14760584.2026.2622690","url":null,"abstract":"Introduction: Neonatal sepsis, a systemic infection occurring in infants within their first 28 days of life, is a leading cause of mortality globally. The burden is especially severe in low- and middle-income countries (LMICs), where incidence and mortality rates are higher than in high-resource settings. Antimicrobial resistance, driven by multidrug-resistant pathogens prevalent in LMICs, further complicates its effective management. Vaccination offers a promising strategy to prevent infections caused by common neonatal sepsis pathogens, potentially reducing sepsis incidence and mitigating resistance.Area covered: This review examines the burden of bacterial pathogens, specifically Group B Streptococcus (GBS), Klebsiella pneumoniae, and Escherichia coli, responsible for neonatal sepsis, drawing from a comprehensive literature search focusing on the last ten years across major databases. It provides an overview of vaccine candidates in clinical development, highlights innovative approaches in preclinical research, and discusses the key challenges associated with vaccine strategies preventing neonatal sepsis.Expert opinion: Given the multivalency of vaccines for neonatal sepsis, innovative technologies are under investigation. Defining correlate of protections has been critical for GBS vaccine development, and may pave the way for vaccines against K. pneumoniae and E. coli. Novel regulatory and clinical strategies, including disease-based rather than pathogen-specific approaches, should be explored.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2622690"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada. 加拿大≥50岁成人使用pneuc -21的成本-效果分析

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-01-14 DOI: 10.1080/14760584.2025.2608811

Peter P Mueller, Marie-Claude Meilleur, Zinan Yi, Amanda Martino, Kwame Owusu-Edusei

{"title":"Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada.","authors":"Peter P Mueller, Marie-Claude Meilleur, Zinan Yi, Amanda Martino, Kwame Owusu-Edusei","doi":"10.1080/14760584.2025.2608811","DOIUrl":"10.1080/14760584.2025.2608811","url":null,"abstract":"Background: This study analyzed the health and economic outcomes of the 21-valent pneumococcal conjugate vaccine (PNEU-C-21; CAPVAXIVE®) compared to either PNEU-C-20 or PNEU-P-23. Cohorts in the cost-effectiveness analyses included vaccine-naïve 57- and 65-year-olds and vaccine-experienced 70-year-olds.Research design and methods: A published Markov model simulated the movement of the Canadian population among four health states: healthy, pneumococcal disease (invasive pneumococcal disease and community-acquired pneumonia attributed to S. pneumoniae), post-meningitis sequelae, and death. The model was populated with published literature and publicly available databases and/or reports. Model inputs included demographic data, epidemiologic data, serotype distribution, vaccine effectiveness, costs, and health-related utilities. The model used a lifetime horizon and 1.5% discounting of costs and life years. Key outcomes included the following: cases, deaths, costs, and incremental cost-effectiveness ratios.Results: The PNEU-C-21 strategy prevented substantially more cases and deaths when compared to the PNEU-C-20 or PNEU-P-23 strategies. For both vaccine-naïve cohorts, the ICERs were dominant for both PNEU-C-21 vs. PNEU-C-20 and PNEU-C-21 vs. PNEU-P-23; among adults aged 70 years, previously vaccinated with PNEU-P-23, PNEU-C-21 was dominant over PNEU-C-20.Conclusions: These results demonstrate that PNEU-C-21 can prevent a substantial number of cases and deaths while remaining highly cost-effective over a range of inputs and scenarios in Canada.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2608811"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy. 意大利慢性阻塞性肺疾病患者单剂RSVPreF3佐剂疫苗预防呼吸道合胞病毒（RSV）的成本效益

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-16 DOI: 10.1080/14760584.2026.2626916

Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, Giancarlo Lorenzini, Fabiano Di Marco, Giovanna Elisa Calabró

{"title":"Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy.","authors":"Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, Giancarlo Lorenzini, Fabiano Di Marco, Giovanna Elisa Calabró","doi":"10.1080/14760584.2026.2626916","DOIUrl":"10.1080/14760584.2026.2626916","url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) increases the risk of severe respiratory syncytial virus (RSV)-related disease. This analysis evaluated the potential public health impact and cost-effectiveness of RSV vaccination with a single dose of adjuvanted RSVPreF3 vaccine over five years in people aged 60-74 years with COPD in Italy.Research design and methods: A static multi-cohort Markov model estimated RSV-related events, costs, and quality-adjusted life-years (QALY) over five years in people aged 60-74 years with COPD in Italy vaccinated with one dose of adjuvanted RSVPreF3, versus no vaccination. Vaccine efficacy and waning data were based on AReSVi-006 Phase III clinical trial results. Other input data came from published literature and official databases. Sensitivity analyses were conducted.Results: A single dose of adjuvanted RSVPreF3 vaccine (75% coverage) was projected to reduce RSV-related acute respiratory infections by 29% and RSV-related hospitalizations and deaths by 38% among patients with COPD aged 60-74 years in Italy. The incremental cost-effectiveness ratio (health system perspective) was €1,306/QALY.Conclusions: These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626916"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-level impact of HPV vaccination: a global systematic review of ecological, cross-sectional, and cohort studies. 人乳头瘤病毒疫苗接种对人群水平的影响：生态、横断面和队列研究的全球系统综述。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-10 DOI: 10.1080/14760584.2026.2667734

Addisu J Zeleke, Laura Reifferscheid, Umar Yunusa, Kelina Gandhi, Megan Kennedy, Manish Sadarangani, Shannon E MacDonald

{"title":"Population-level impact of HPV vaccination: a global systematic review of ecological, cross-sectional, and cohort studies.","authors":"Addisu J Zeleke, Laura Reifferscheid, Umar Yunusa, Kelina Gandhi, Megan Kennedy, Manish Sadarangani, Shannon E MacDonald","doi":"10.1080/14760584.2026.2667734","DOIUrl":"10.1080/14760584.2026.2667734","url":null,"abstract":"Background: Human papillomavirus (HPV) causes approximately 4.5% of cancers globally, with the highest burden in low- and middle-income countries (LMICs). Since their introduction in 2006, HPV vaccination programs have led to substantial declines in HPV-related outcomes, although impact varies across settings.Research design and methods: We conducted a systematic review to evaluate the population-level impact of HPV vaccination on HPV infection, cervical intraepithelial neoplasia grade 2 or higher (CIN2+), genital warts, invasive cervical cancer (ICC), and oropharyngeal cancer (OPC), and examined the influence of coverage, age at initiation, and vaccine type. The review followed PRISMA 2020.Results: Of 13,549 records screened, 63 were included: 9 assessed HPV infection, 24 on CIN2+, 25 on genital warts, and 7 on ICC. Greatest reductions were observed in settings with at least 70% coverage and early vaccination prior to sexual debut, typically achieved through school-based programs. Reported declines ranged from 58-100% for HPV infection, 30-88% for CIN2+, 60-90% for genital warts, and 70-88% for ICC.Conclusions: HPV vaccination offers strong protection, especially when delivered early and at high coverage within schools. Expanding access and prioritizing underserved populations are essential to achieving global cancer prevention goals. Limitations include heterogeneity across designs, outcome definitions, and follow-up.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2667734"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions. 慢性克氏锥虫感染疫苗：进展、挑战和未来方向。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-22 DOI: 10.1080/14760584.2026.2632658

Eric Dumonteil, Claudia Herrera

{"title":"Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions.","authors":"Eric Dumonteil, Claudia Herrera","doi":"10.1080/14760584.2026.2632658","DOIUrl":"10.1080/14760584.2026.2632658","url":null,"abstract":"Introduction: Chronic infections with Trypanosoma cruzi can lead to Chagas disease, with cardiac and/or digestive debilitating manifestations. There has been a renewed interest in vaccine development against this neglected tropical disease in the past decades.Areas covered: Vaccines ranging from live attenuated to recombinant subunit, nucleic acid, bacterial, viral and algal vectors, targeting various parasite antigens have been tested in mice as preventative and therapeutic vaccine against clinical disease progression as well as in the context of pregnancy to prevent congenital transmission and other adverse birth outcomes. A few of these vaccine candidates have been tested in dogs and non-human primates. Further clinical development faces several challenges associated with slow disease progression and the lack of biomarkers, the diversity of parasite strains, complex host-parasite relationship, among others.Expert opinion: Pre-clinical studies broadly support the clinical development of a Chagas disease vaccine, particularly for a therapeutic vaccine. Synergy with drug development efforts, which face many of the same challenges, may provide new opportunities to strengthen clinical development and trials of drugs, vaccines and combined therapies.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2632658"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica. 对哥斯达黎加使用COVID-19疫苗的疫苗接种战略的潜在公共卫生和经济影响以及成本效益进行建模。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-26 DOI: 10.1080/14760584.2026.2634800

Juan José Baldi-Castro, Carlos Fernando Mendoza, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Ben Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada

{"title":"Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica.","authors":"Juan José Baldi-Castro, Carlos Fernando Mendoza, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Ben Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada","doi":"10.1080/14760584.2026.2634800","DOIUrl":"10.1080/14760584.2026.2634800","url":null,"abstract":"Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants.Research design and methods: Using a previously published, combined Markov-decision tree model adapted for Costa Rica, this study estimated the outcomes of different vaccination strategies with BNT162b2 COVID-19 mRNA vaccine, targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Scenario analyses that implemented variation in COVID-19 incidence and sensitivity analyses were both conducted to assess uncertainty.Results: Compared to no adapted vaccine, the vaccination strategy in older adults aged ≥65 years and the high-risk population aged 18-64 years was estimated to prevent 3704 symptomatic cases, 3670 outpatient cases, 35 hospitalizations, 102 lost quality-adjusted life-years (QALYs), and one death, translating to total direct and societal cost savings of US$9,465,324 and US$10,569,883, respectively. Expanding vaccination to adults aged ≥60 years and high-risk individuals aged 18-59 years further increased benefits.Conclusions: Implementing an adapted COVID-19 vaccine strategy for high-risk and older adults in Costa Rica is expected to be cost-saving, with broader age group eligibility yielding even greater benefits.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2634800"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a global framework to assess a country's readiness and resilience to introduce a new vaccine or improve uptake of an underutilized vaccine. 制定一个全球框架，以评估一个国家在引进新疫苗或改善未充分利用疫苗的吸收方面的准备和复原力。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-20 DOI: 10.1080/14760584.2026.2674688

Vaneesha Monk, Aomesh Bhatt, Rachel Mitrovich, Rebeccah Slater, Lindsay V Hermany, Luke Baxter, Alexandra Bhatti, Natasha Hansen, Maria Cobo, Samantha Vanderslott, Thomas Foulkes, Mark Connolly, Amanda L Eiden

{"title":"Developing a global framework to assess a country's readiness and resilience to introduce a new vaccine or improve uptake of an underutilized vaccine.","authors":"Vaneesha Monk, Aomesh Bhatt, Rachel Mitrovich, Rebeccah Slater, Lindsay V Hermany, Luke Baxter, Alexandra Bhatti, Natasha Hansen, Maria Cobo, Samantha Vanderslott, Thomas Foulkes, Mark Connolly, Amanda L Eiden","doi":"10.1080/14760584.2026.2674688","DOIUrl":"10.1080/14760584.2026.2674688","url":null,"abstract":"Background: Successful, resilient immunization programs must address complex factors to support vaccine introduction and uptake. We developed an evidence-based tool for use with different populations and vaccines to (i) assess readiness for new and underutilized vaccines, and (ii) assess resilience of existing immunization programs.Research design and methods: In Phase 1, we synthesized findings from two published literature reviews to inform a prototype Immunization Program Resilience and Readiness Assessment Tool. In Phase 2, we conducted interviews, surveys, and expert forums with Key Opinion Leaders (KOLs). Phase 2a included 16 global KOLs from 13 countries or regions, refining and renaming the resilience and readiness prototype tool into readiness and resilience global framework. Phase 2b included seven KOLs from the United States (US), refining the prototype tool into a US-specific tool. Phase 3 involved eleven KOLs from four countries who field-tested the global framework for comprehensiveness, relevance, acceptability, and feasibility.Results: We created an evidence-based global framework and context-specific US tool. Field-testing strongly demonstrated the comprehensiveness, relevance, acceptability, and feasibility of use of the global framework.Conclusions: This framework can support more efficient, equitable, and sustainable immunization programs worldwide. Given the rising nature of vaccine hesitancy, budget constraints, and competing health priorities, there is an increased need for systematic assessment and evidence-based decision-making.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2674688"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0-14 years in Jiangsu Province, China. 江苏省0 ~ 14岁儿童水痘流行病学特征及突发性水痘相关因素分析

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-29 DOI: 10.1080/14760584.2026.2708202

Mei Li, Yan Xu, Yurong Li, Qiang Chen, Chengmei Jia, Dongsheng Liu, Xiaozhe Song, Xue Yan Sha, Yuan Ren, Zhiguo Wang, Xiang Sun

{"title":"Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0-14 years in Jiangsu Province, China.","authors":"Mei Li, Yan Xu, Yurong Li, Qiang Chen, Chengmei Jia, Dongsheng Liu, Xiaozhe Song, Xue Yan Sha, Yuan Ren, Zhiguo Wang, Xiang Sun","doi":"10.1080/14760584.2026.2708202","DOIUrl":"10.1080/14760584.2026.2708202","url":null,"abstract":"Background: This study aimed to explore the epidemiological characteristics of varicella and breakthrough varicella (BV), as well as factors associated with the BV proportion during 2021-2024.Research design and methods: Data on varicella cases aged 0-14 years were extracted from the national surveillance system and linked to individual immunization records. Logistic and linear regression were adopted.Results: Among 162,844 cases, 34.3% were BV, and 10-14-year age group increased significantly from 24.7% in 2021 to 61.1% in 2024 (p < 0.001). During 2023-2024, older age groups showed lower BV proportion (5-9 years: OR = 0.49; 10-14 years: OR = 0.58; both p < 0.001), while the 10-14 years group showed higher BV proportion (OR = 1.08, p < 0.001) during 2021-2022. Autumn onset (OR = 1.14) and cases from central (OR = 1.39) and southern Jiangsu (OR = 2.31) were positively associated with BV proportion (all p < 0.001). The median breakthrough interval among one-dose recipients was 7.5 years, with 61.7% of cases occurring ≥6 years post-vaccination.Conclusion: Varicella burden in Jiangsu is shifting to older children. Strengthening two-dose varicella vaccination and maintaining routine vaccination coverage in young children are crucial for varicella control.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2708202"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic. 对多米尼加共和国使用适应型COVID-19疫苗的疫苗接种战略的潜在公共卫生和经济影响以及成本效益进行建模。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-06-27 DOI: 10.1080/14760584.2026.2694383

Carlos Fernando Mendoza, Juan José Baldi-Castro, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Benjamin Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada

{"title":"Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.","authors":"Carlos Fernando Mendoza, Juan José Baldi-Castro, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Benjamin Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada","doi":"10.1080/14760584.2026.2694383","DOIUrl":"10.1080/14760584.2026.2694383","url":null,"abstract":"Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants.Research design and methods: Using a previously published combined Markov-decision tree model adapted for the Dominican Republic, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Scenario analyses that included variations in the incidence of COVID-19 and sensitivity analyses were conducted to assess uncertainty.Results: Compared to no vaccination, the vaccination strategy targeting adults aged ≥65 years and the high-risk population was estimated to prevent 9,272 symptomatic cases, 9,184 outpatient cases, 88 hospitalizations, 239 lost quality-adjusted life-years (QALYs), and three deaths, translating to total direct and societal cost savings of US$11,064,184 and US$12,662,370, respectively. Expanding vaccination to adults aged ≥60 years and high-risk individuals aged 18-59 years further increased public health and economic benefits.Conclusions: Implementing an adapted COVID-19 vaccine strategy for high-risk and adults aged ≥65 in the Dominican Republic is expected to be cost-saving, with broader age group coverage yielding even greater benefits.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2694383"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responses. 病毒样颗粒疫苗：从抗原结构到抗原呈递和适应性免疫反应。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-10-14 DOI: 10.1080/14760584.2026.2746121

Zihan Zhang, Huiwen Zheng, Longding Liu

{"title":"Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responses.","authors":"Zihan Zhang, Huiwen Zheng, Longding Liu","doi":"10.1080/14760584.2026.2746121","DOIUrl":"https://doi.org/10.1080/14760584.2026.2746121","url":null,"abstract":"Introduction: Virus-like particles (VLPs) mimic key structural features of native viruses while lacking a replication-competent viral genome, combining favorable safety with multivalent antigen presentation and strong immunogenicity. Yet, how VLP design influences the quality and persistence of adaptive immunity remains incompletely understood.Areas covered: This review examines relevant literature identified through targeted searches on recent advances in VLP engineering, with emphasis on particle architecture, antigen-display strategies, and structural determinants of immune recognition. We discuss how VLPs facilitate antigen presentation by antigen-presenting cells and shape CD4+ and CD8+ T-cell responses, immune memory, and T follicular helper cell-B-cell interactions within germinal centers. Emerging approaches linking VLP design with humoral and cellular immunity are also considered.Expert opinion: The next generation of VLP vaccines will require a transition from empirical enhancement of immunogenicity toward precision engineering of immune responses. A major challenge is to establish robust and transferable structure-immunity relationships while addressing manufacturing feasibility, quality control, potency assessment, and product comparability. Advances in computational protein design, structural biology, and high-dimensional immune profiling are expected to enable increasingly quantitative and mechanism-based optimization of VLP platforms. However, fully predictive control over human immune responses will remain a complex challenge.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2746121"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0